Skip to main content
. 2021 Nov 17;54(4):1081–1090. doi: 10.4143/crt.2021.890

Fig. 2.

Fig. 2

Survival analysis between different estrogen receptor (ER) subgroups in early stage invasive ductal carcinoma patients. Difference in 5-year recurrence-free survival between ERhigh/ERlow/ER (A), ERhigh/ER (B), ERhigh/ERlow (C), and ERlow/ER (D) patients. ER, estrogen receptor negative; ERhigh, estrogen receptor high positive; ERlow, estrogen receptor low positive.